GlassScriptPhysician profile
Charles A Moore
NPI 1417319807
$6,014.56
in general payments reported to CMS, 2019-2025
20 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $350 · 2021: $1,703 · 2022: $369 · 2023: $373 · 2024: $1,976 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007 · Travel and Lodging: $861 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.39 |
| Travel and Lodging | $860.89 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,520.87 | 2021-2025 | Inspire |
| Medical Device Business Services, INC. | $648.48 | 2020-2021 | |
| Stryker Corporation | $614.47 | 2019-2021 | |
| Medtronic, INC. | $424.10 | 2021-2024 | Stealthstation S8 Platform, N/A |
| Acclarent, INC | $305.14 | 2022-2023 | Trudi Nav Cable, Acclarent Aera |
| Genzyme Corporation | $270.24 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $243.15 | 2022-2025 | Dupixent |
| Cochlear Americas | $185.40 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Integra Lifesciences Corporation | $146.31 | 2021 | |
| Axogen | $133.92 | 2025 | |
| Intersect Ent, INC. | $130.90 | 2019 | |
| Optinose US, INC. | $103.39 | 2022-2024 | |
| Glaxosmithkline, LLC. | $70.06 | 2024-2025 | Nucala |
| Checkpoint Surgical, INC | $61.71 | 2021 | |
| Phadia US INC. | $48.51 | 2023 | Immunocap |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $36.83 | 2024 | Karbinal |
| Davol INC. | $25.02 | 2023 | Arista Ah Flexitip |
| Organogenesis INC. | $18.00 | 2022 | |
| Hikma Pharmaceuticals USA | $15.99 | 2024 | Ryaltris |
| Kaleo, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.